Clinical Trial Update: hUC Mesenchymal Stem Cells (19#iSCLife®-LC) in the Treatment of Decompensated Hepatitis b Cirrhosishepatitis b Cirrhosis [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial is evaluating hUC mesenchymal stem cells (19#iSCLife®-LC) for decompensated hepatitis B cirrhosis. The study is sponsored by Sclnow Bio…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• 19#iSCLife®-LC (human umbilical cord-derived mesenchymal stem cells)

Snippet

Sponsor: Sclnow Biotechnology Co., Ltd. | Conditions: Hepatitis B | Phase 1 | Status: RECRUITING